Evotec (ETR:EVT) Given a €34.00 Price Target by Warburg Research Analysts

Evotec (ETR:EVTGet Rating) has been assigned a €34.00 ($34.00) target price by investment analysts at Warburg Research in a research report issued on Wednesday, Borsen Zeitung reports. Warburg Research’s target price suggests a potential upside of 87.12% from the stock’s previous close.

Several other brokerages have also issued reports on EVT. Deutsche Bank Aktiengesellschaft set a €26.00 ($26.00) price target on shares of Evotec in a research note on Wednesday, October 19th. Morgan Stanley set a €32.00 ($32.00) price target on shares of Evotec in a research note on Wednesday, August 10th. Royal Bank of Canada set a €35.00 ($35.00) price target on shares of Evotec in a research note on Wednesday. Finally, Jefferies Financial Group set a €38.00 ($38.00) price objective on shares of Evotec in a research note on Wednesday.

Evotec Trading Up 4.7 %

Shares of EVT stock opened at €18.17 ($18.17) on Wednesday. The company has a 50 day moving average of €19.08 and a 200-day moving average of €22.73. The company has a quick ratio of 3.24, a current ratio of 3.57 and a debt-to-equity ratio of 37.88. Evotec has a 12-month low of €16.18 ($16.18) and a 12-month high of €45.30 ($45.30). The firm has a market cap of $3.22 billion and a P/E ratio of 434.00.

About Evotec

(Get Rating)

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.

Read More

Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.